On 17 July 2024, ASLAN Pharmaceuticals announced that it has filed for voluntary liquidation of its Singaporean sole operating subsidiary and will itself also apply for liquidation. ASLAN reports that the appointed liquidator of the Singapore subsidiary will seek “potential strategic alternatives” for the company’s eblasakimab (a first-in-class monoclonal antibody) and farudodstat.
In April 2024, ASLAN had announced positive interim results from a Phase 2 Study (TREK-DX) of eblasakimab in moderate-to-severe atopic dermatitis adult patients previously treated with dupilumab. ASLAN entered into an exclusive licence with Zenyaku Kogyo in June 2023 to develop and commercialise eblasakimab to treat atopic dermatitis in Japan.